Abstract

Glycated albumin (GA) and the variation of consecutive GA measurements are demonstrated to be associated with chronic diabetic complications. Compared to hemoglobin A1c, GA can provide more accurate glycemic information in patients with specific clinical conditions such as hemoglobin diseases, end-stage renal diseases on dialysis, or in patients who experience drastic changes in glucose level. Meanwhile, the use of GA is limited in several clinical situations such as obesity, autoimmune diseases, and predicting adverse pregnancy outcomes and arterial stiffness. This review summarized the clinical significance and research progress of GA and its variability.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.